Clinical Trial Update: Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing semaglutide tablets with empagliflozin tablets for type 2 diabetes and obesity was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: WITHDRAWN